Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

apceth’s First-In-Man, First-In-Class Clinical Trial with MSCs is Now Enrolling

Published: Monday, January 27, 2014
Last Updated: Monday, January 27, 2014
Bookmark and Share
TREAT ME Phase I/II clinical trial for patients suffering from advanced adenocarcinoma of the gastro-intestinal tract.

As a world first, apceth has announced that the TREAT ME Phase I/II clinical trial for patients suffering from advanced adenocarcinoma of the gastro-intestinal tract has commenced. This is the first clinical trial world-wide with genetically-modified mesenchymal stromal cells (MSCs).

This innovative next-generation MSC therapy is based on cells harvested from the patient's own (autologous) bone marrow, which are processed, genetically modified and re-infused into the patient.

The cells specifically target the tumor, or its metastases, where the cytotoxic gene product is selectively activated, increasing local efficacy with reduced systemic toxicity, one of the main problems of systemic chemotherapy.

This unique principle is also applicable to other cancer types. apceth intends to advance this treatment to an off-the-shelf product where cells obtained for healthy donors will be used to treat multiple patients.

“This is an important milestone for all of us at apceth who strive to produce truly innovative products that make a real difference to patients” said apceth’s CEO, Dr Christine Guenther.

Dr Guenther continued, “We are the first to use next-generation MSC-based therapies in the clinic and this sets us apart from the competition. This is a platform technology that carries significant potential and represents the future of cell therapies”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

apceth Names Dr Stefanos Theoharis Chief Business Officer
Dr Stefanos Theoharis will lead apceth’s business development and business operations and promote the continued expansion of apceth’s GMP manufacturing business.
Thursday, September 05, 2013
apceth Receives Approval for a Clinical Cancer Trial with Adult Mesenchymal Stem Cells
apceth's first innovative cellular anti-cancer drug based on modified mesenchymal stem cells enters Phase I / II of clinical testing.
Friday, June 14, 2013
apceth Received the Second Round of Funding for Its Innovative Stem Cell-Based Cancer Therapeutic
Development of apceth’s first innovative “Advanced Therapy Medicinal Product” based on modified adult stem cells for cancer therapy.
Wednesday, February 06, 2013
apceth Received Extended Manufacturer's Licence for Somatic Cell Therapeutics at the Ottobrunn Site
Four new cleanrooms expand capacity to a total of 600 m2.
Tuesday, November 01, 2011
apceth Extends Top Management
Prof. Ralf Huss, previously Global Head of the Therapeutic Cell Initiative at Roche, joins the management board of apceth GmbH & Co. KG, Munich.
Monday, October 10, 2011
apceth Starts First Phase I/II Clinical Study on Somatic Cell Therapy for pAOD
Study investigates tolerability and efficacy of apceth's somatic cell therapeutics for treatment of pAOD after angioplasty.
Tuesday, August 23, 2011
apceth is Granted a Manufacturer's Licence for Somatic Cell Therapy
Manufacturer's licence enables contract manufacture and development of innovative cell preparations for contractual partners.
Tuesday, August 09, 2011
Scientific News
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Edited Stem Cells Offer Hope of Precision Therapy for Blindness
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Newfound Strength in Regenerative Medicine
A promising new approach uses direct mechanical stimulation to repair severely damaged skeletal muscles.
Mapping out Cell Conversion
Researchers develop algorithm that takes the field of cell reprogramming forward.
Donor's Genotype Controls the Differentiation of IPS Cells
Pluripotent stem cells derived from different cell types are equally susceptible to reprogramming, indicates a recent study by the University of Helsinki and the National Institute for Health and Welfare, Finland. However, the genotype of the donor strongly influences the differentiation of the stem cell.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!